BioLineRx Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.79
- Today's High:
- $2.1
- Open Price:
- $1.97
- 52W Low:
- $0.55
- 52W High:
- $1.98
- Prev. Close:
- $2.03
- Volume:
- 3032588
Company Statistics
- Market Cap.:
- $96.66 million
- Book Value:
- 0.63
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.83%
- Return on Equity TTM:
- -62.78%
Company Profile
BioLineRx Ltd had its IPO on 2011-07-25 under the ticker symbol BLRX.
The company operates in the Healthcare sector and Biotechnology industry. BioLineRx Ltd has a staff strength of 49 employees.
Stock update
Shares of BioLineRx Ltd opened at $1.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.79 - $2.1, and closed at $1.99.
This is a -1.97% slip from the previous day's closing price.
A total volume of 3,032,588 shares were traded at the close of the day’s session.
In the last one week, shares of BioLineRx Ltd have slipped by -1.49%.
BioLineRx Ltd's Key Ratios
BioLineRx Ltd has a market cap of $96.66 million, indicating a price to book ratio of 0.7645 and a price to sales ratio of 0.
In the last 12-months BioLineRx Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-31463000. The EBITDA ratio measures BioLineRx Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BioLineRx Ltd’s operating margin was 0% while its return on assets stood at -27.83% with a return of equity of -62.78%.
In Q1, BioLineRx Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
BioLineRx Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.2
Its diluted EPS in the last 12-months stands at $-0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.2. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioLineRx Ltd’s profitability.
BioLineRx Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0704. Its price to sales ratio in the trailing 12-months stood at 0.
BioLineRx Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $68.65 million
- Total Liabilities
- $12.04 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $129000
- Dividend Payout Ratio
- 0%
BioLineRx Ltd ended 2024 with $68.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $68.65 million while shareholder equity stood at $39.11 million.
BioLineRx Ltd ended 2024 with $0 in deferred long-term liabilities, $12.04 million in other current liabilities, 27100000.00 in common stock, $-342154000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.07 million and cash and short-term investments were $43.29 million. The company’s total short-term debt was $2,937,000 while long-term debt stood at $8.24 million.
BioLineRx Ltd’s total current assets stands at $44.33 million while long-term investments were $0 and short-term investments were $34.22 million. Its net receivables were $302000.00 compared to accounts payable of $7.14 million and inventory worth $0.
In 2024, BioLineRx Ltd's operating cash flow was $0 while its capital expenditure stood at $129000.
Comparatively, BioLineRx Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.99
- 52-Week High
- $1.98
- 52-Week Low
- $0.55
- Analyst Target Price
- $9.67
BioLineRx Ltd stock is currently trading at $1.99 per share. It touched a 52-week high of $1.98 and a 52-week low of $1.98. Analysts tracking the stock have a 12-month average target price of $9.67.
Its 50-day moving average was $1.6 and 200-day moving average was $1.12 The short ratio stood at 3.2 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 1089% are held by institutions.
Frequently Asked Questions About BioLineRx Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi’in, Israel.